XML 61 R24.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Revenue Revenue | 12 Months Ended
--- | ---
Dec. 31, 2019
Revenue from Contract with Customer [Abstract] |
Revenue from Contract with Customer [Text Block] | NOTE O – REVENUE We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes in our consolidated statements of operations. The following tables disaggregate our revenue from contracts with customers by business and geographic region (in millions):
| Year Ended December 31,
| 2019 |  | 2018 |  | 2017
Businesses | U.S. |  | OUS |  | Total |  | U.S. |  | OUS |  | Total |  | U.S. |  | OUS |  | Total
Endoscopy | $ | 1,080 |  |  | $ | 814 |  |  | $ | 1,894 |  |  | $ | 980 |  |  | $ | 781 |  |  | $ | 1,762 |  |  | $ | 894 |  |  | $ | 724 |  |  | $ | 1,619 |
Urology and Pelvic Health | 1,005 |  |  | 408 |  |  | 1,413 |  |  | 864 |  |  | 381 |  |  | 1,245 |  |  | 785 |  |  | 339 |  |  | 1,124 |
Cardiac Rhythm Management | 1,135 |  |  | 804 |  |  | 1,939 |  |  | 1,159 |  |  | 792 |  |  | 1,951 |  |  | 1,135 |  |  | 760 |  |  | 1,895 |
Electrophysiology | 148 |  |  | 180 |  |  | 329 |  |  | 150 |  |  | 161 |  |  | 311 |  |  | 136 |  |  | 142 |  |  | 278 |
Neuromodulation | 695 |  |  | 178 |  |  | 873 |  |  | 624 |  |  | 155 |  |  | 779 |  |  | 517 |  |  | 118 |  |  | 635 |
Interventional Cardiology | 1,293 |  |  | 1,522 |  |  | 2,816 |  |  | 1,154 |  |  | 1,436 |  |  | 2,590 |  |  | 1,122 |  |  | 1,297 |  |  | 2,419 |
Peripheral Interventions | 741 |  |  | 651 |  |  | 1,392 |  |  | 608 |  |  | 579 |  |  | 1,187 |  |  | 575 |  |  | 506 |  |  | 1,081 |
Specialty Pharmaceuticals | 70 |  |  | 11 |  |  | 81 |  |  | n/a |  |  | n/a |  |  | n/a |  |  | n/a |  |  | n/a |  |  | n/a |
Net Sales | $ | 6,167 |  |  | $ | 4,569 |  |  | $ | 10,735 |  |  | $ | 5,538 |  |  | $ | 4,286 |  |  | $ | 9,823 |  |  | $ | 5,162 |  |  | $ | 3,885 |  |  | $ | 9,048 |
| Year Ended December 31,
Geographic Regions | 2019 |  | 2018 |  | 2017
U.S. | $ | 6,097 |  |  | $ | 5,538 |  |  | $ | 5,162 |
EMEA (Europe, Middle East and Africa) | 2,264 |  |  | 2,176 |  |  | 1,940 |
APAC (Asia-Pacific) | 1,898 |  |  | 1,727 |  |  | 1,587 |
LACA (Latin America and Canada) | 395 |  |  | 383 |  |  | 358 |
Medical Devices | 10,654 |  |  | 9,823 |  |  | 9,048 |
U.S. | 70 |  |  | n/a |  |  | n/a |
OUS | 11 |  |  | n/a |  |  | n/a |
Specialty Pharmaceuticals | 81 |  |  | n/a |  |  | n/a |
Net Sales | $ | 10,735 |  |  | $ | 9,823 |  |  | $ | 9,048 |
Emerging Markets (1) | $ | 1,252 |  |  | $ | 1,097 |  |  | $ | 931 |
(1) | We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets; effective January 1, 2019, we updated our list of Emerging Market countries. Our current list is comprised of the following countries: Argentina, Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Thailand, Turkey and Vietnam. We have revised prior year amounts to the current year’s presentation.
Contract liabilities are classified within Other current liabilities and Other long-term liabilities on our accompanying consolidated balance sheets. Our deferred revenue balance was $400 million as of December 31, 2019 and $373 million as of December 31, 2018. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. We recognized revenue of $143 million in 2019 that was included in the above December 31, 2018 contract liability balance. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred. Refer to Note A – Significant Accounting Policies for additional information on our accounting policies relating to revenue recognition.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -URI http://asc.fasb.org/topic&trid=49130388 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -URI http://asc.fasb.org/topic&trid=2122369 + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration